Luxin Venture Capital Contributes to Boston's Intarcia Therapeutics $215 Million Round
September 16, 2016 at 05:53 AM EDT
Luxin Venture Capital of Shandong Province participated in the first closing of the latest funding round for Boston's Intarcia Therapeutics. Intarcia is developing a novel delivery device for type 2 diabetes, the Medici Drug Delivery System™. The initial close raised $215 million. Intarcia anticipates a much larger close in Q4. Intarcia has completed three Phase III trials of its matchstick-sized implantable device that metes out a year-long supply of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. More details.... Stock Symbol: (SHA: 600783) Share this with colleagues: // //